EV/EBIT
Enterprise Value to EBIT

47.6
Current
32.5
Median
16
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
47.6
=
Enterprise Value
2.4B EUR
/
EBIT
49.6m EUR
Market Cap EV/EBIT
ES
Almirall SA
MAD:ALM
2.3B EUR 47.6
US
Eli Lilly and Co
NYSE:LLY
684.8B USD 36.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
369.5B USD 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 15.3
CH
Roche Holding AG
SIX:ROG
208.2B CHF 11.1
CH
Novartis AG
SIX:NOVN
184.6B CHF 13.8
UK
AstraZeneca PLC
LSE:AZN
162.6B GBP 197.2
US
Merck & Co Inc
NYSE:MRK
192.2B USD 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
133.3B USD 10.3
EBIT Growth EV/EBIT to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBIT: 1 701.4
47.6
56%
0.9
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
27.3
2-Years Forward
EV/EBIT
17.8
3-Years Forward
EV/EBIT
12.4